Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Background Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin polymerase inhibitors) and upcoming (e.g. aurora kinase inhibitors) compounds. Design and Methods We assessed proliferation using gene expression-based indices in 757 samples including independent cohorts of 298 and 345 samples of CD138-purified myeloma cells from previously untreated patients undergoing high-dose chemotherapy, together with clinical prognostic factors, chromosomal aberrations, and gene expression-based high-risk scores. Results In the two cohorts, 43.3% and 39.4% of the myeloma cell samples showed a proliferation index above the median plus three standard deviations of normal bone marrow plasma cells. Malignant plasma cells of patients in advanced stages or those harboring disease progression-associated gain of 1q21 or deletion of 13q14.3 showed significantly higher proliferation indices; patients with gain of chromosome 9, 15 or 19 (hyperdiploid samples) had significantly lower proliferation indices. Proliferation correlated with the presence of chromosomal aberrations in metaphase cytogenetics. It was significantly predictive for event-free and overall survival in both cohorts, allowed highly predictive risk stratification (e.g. event-free survival 12.7 versus 26.2 versus 40.6 months, P<0.001) of patients, and was largely independent of clinical prognostic factors, e.g. serum β2-microglobulin, International Staging System stage, associated high-risk chromosomal aberrations, e.g. translocation t(4;14), and gene expression-based high-risk scores. Conclusions Proliferation assessed by gene expression profiling, being independent of serum-β2-microglobulin, International Staging System stage, t(4;14), and gene expression-based risk scores, is a central prognostic factor in multiple myeloma. Surrogating a biological targetable variable, gene expression-based assessment of proliferation allows selection of patients for risk-adapted anti-proliferative treatment on the background of conventional and gene expression-based risk factors.

[1]  G. Malerba,et al.  Supplementary Figure S4 , 2012 .

[2]  D. Fanelli,et al.  Supplementary Table S3 , 2007 .

[3]  G. Malerba,et al.  Supplementary Figure S2 , 2012 .

[4]  A. Chinnaiyan,et al.  Supplementary Figure S3 , 2012 .

[5]  T. Rème,et al.  Induction of angiogenesis by normal and malignant plasma cells. , 2009, Blood.

[6]  Axel Benner,et al.  Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. , 2008, Blood.

[7]  J. D. Vos,et al.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis , 2009, Oncogene.

[8]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Rainer Spang,et al.  Microarray Based Diagnosis Profits from Better Documentation of Gene Expression Signatures , 2008, PLoS Comput. Biol..

[10]  Hartmut Goldschmidt,et al.  A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments , 2008, BMC Bioinformatics.

[11]  Paolo G. V. Martini,et al.  PANP - a New Method of Gene Detection on Oligonucleotide Expression Arrays , 2007, 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering.

[12]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[13]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[14]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[15]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[16]  John Crowley,et al.  Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. , 2006, Blood.

[17]  J. D. Vos,et al.  Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS). , 2005 .

[18]  D. Hose,et al.  Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics , 2005, Genes, chromosomes & cancer.

[19]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Pantesco,et al.  The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. , 2005, Blood.

[21]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[22]  P. Renhowe,et al.  Inhibitors of kinesin motor proteins--research and clinical progress. , 2005, Current opinion in drug discovery & development.

[23]  J. Penninger,et al.  The role of endothelial PI3Kgamma activity in neutrophil trafficking. , 2005, Blood.

[24]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Magrangeas,et al.  Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma , 2005, Leukemia.

[26]  T. Rème,et al.  A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival. , 2004 .

[27]  F. Magrangeas,et al.  Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma. , 2004 .

[28]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[29]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[30]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[31]  E. Stathopoulos,et al.  Ki-67 Proliferation Index: Correlation With Prognostic Parameters and Outcome in Multiple Myeloma , 2004, American journal of clinical oncology.

[32]  A. Murray,et al.  Recycling the Cell Cycle Cyclins Revisited , 2004, Cell.

[33]  R. Bataille,et al.  Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report , 2004 .

[34]  P. Bergsagel,et al.  Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma , 2003, Immunological reviews.

[35]  K. Tarte,et al.  Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. , 2002, Blood.

[36]  T. Therneau,et al.  A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. , 2001, Blood.

[37]  H. Kaufmann,et al.  Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. , 2000, Blood.

[38]  J. D. Vos,et al.  Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors , 2000, Leukemia.

[39]  H. Kaufmann,et al.  Deletion of 13 q 14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization , 2000 .

[40]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Therneau,et al.  Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders , 1999, British journal of haematology.

[42]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[43]  K. Tarte,et al.  A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. , 1998, Blood.

[44]  R. Lamerz,et al.  Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase. , 1995, Journal of clinical pathology.

[45]  Marcos González,et al.  A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells , 1995 .

[46]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[47]  J. S. San Miguel,et al.  A new staging system for multiple myeloma based on the number of S-phase plasma cells. , 1995, Blood.

[48]  M. Jourdan,et al.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.

[49]  W. O'Fallon,et al.  Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma , 1993 .

[50]  Lust,et al.  Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.

[51]  W. O'Fallon,et al.  Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. , 1988, Blood.

[52]  T. Habermann,et al.  Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. , 1987, Mayo Clinic proceedings.

[53]  B. Bast,et al.  Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique , 1986, British journal of haematology.

[54]  B. Durie.  Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.

[55]  F. Mandelli,et al.  Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy , 1984, British journal of haematology.

[56]  B. Barlogie,et al.  Ploidy and proliferative characteristics in monoclonal gammopathies. , 1982, Blood.

[57]  B. Barlogie,et al.  The growth fraction of human myeloma cells. , 1981, Blood.

[58]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[59]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.